Celldex Therapeutics’ (CLDX) Buy Rating Reiterated at HC Wainwright

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $80.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 293.89% from the company’s current price.

A number of other analysts also recently weighed in on CLDX. UBS Group assumed coverage on shares of Celldex Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $44.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $56.50.

Celldex Therapeutics Price Performance

NASDAQ CLDX opened at $20.31 on Friday. Celldex Therapeutics has a 1-year low of $20.25 and a 1-year high of $53.18. The business has a 50 day simple moving average of $23.95 and a two-hundred day simple moving average of $29.04. The stock has a market capitalization of $1.35 billion, a PE ratio of -7.90 and a beta of 1.60.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. On average, analysts anticipate that Celldex Therapeutics will post -2.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Celldex Therapeutics

Several hedge funds have recently added to or reduced their stakes in CLDX. KBC Group NV lifted its stake in Celldex Therapeutics by 31.2% in the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Celldex Therapeutics by 2.1% in the fourth quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company’s stock worth $1,064,000 after buying an additional 871 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 878 shares during the last quarter. Swiss National Bank boosted its holdings in Celldex Therapeutics by 1.2% during the 4th quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company’s stock valued at $2,964,000 after acquiring an additional 1,400 shares during the period. Finally, Teachers Retirement System of The State of Kentucky boosted its holdings in Celldex Therapeutics by 5.1% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company’s stock valued at $1,449,000 after acquiring an additional 2,070 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.